- $6.41m
- $9.52m
- $4.92m
- 54
- 41
- 65
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.21 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -47.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 4.32 | 4.56 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Stemtech Corporation is a global network marketing company that develops science-based products, which support wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. The Company is also known as Stem Cell Nutrition Company. The Company's products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. These products are marketed internationally by the Companies subsidiaries and through independent distributors. The Company markets its products under various brands, which include RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze (Electromagnetic Frequency blocker). It also introduced a skincare product, Cellect One Rapid Renew Stem Cell Peptide Night Cream. Its segments include North America, Latin America and Asia.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- September 4th, 2009
- Public Since
- September 15th, 2014
- No. of Employees
- 45
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 104,476,731
- Address
- 4851 Tamiami Trail North, Suite 200, NAPLES, 34103
- Web
- https://www.stemtech.com/
- Phone
- +1 9547156000
- Auditors
- K.R.Margetson Ltd.
Upcoming Events for STEK
Similar to STEK
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 23:28 UTC, shares in Stemtech are trading at $0.05. This share price information is delayed by 15 minutes.
Shares in Stemtech last closed at $0.05 and the price had moved by -20.1% over the past 365 days. In terms of relative price strength the Stemtech share price has underperformed the S&P500 Index by -32.95% over the past year.
There is no consensus recommendation for this security.
Stemtech does not currently pay a dividend.
Stemtech does not currently pay a dividend.
Stemtech does not currently pay a dividend.
To buy shares in Stemtech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.05, shares in Stemtech had a market capitalisation of $5.63m.
Here are the trading details for Stemtech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: STEK
Based on an overall assessment of its quality, value and momentum Stemtech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Stemtech. Over the past six months, its share price has outperformed the S&P500 Index by +56.05%.
As of the last closing price of $0.05, shares in Stemtech were trading +27.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Stemtech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Stemtech's management team is headed by:
- Charles Arnold - CEO
- James Cardwell - CFO
- John Meyer - COO
- John Thatch - DRC